Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981192 | 0.86 | ALDH1A1 (0.37) | MAPK1ALDH1A1 | |
| SCHEMBL9750799 | 0.83 | MAPK1 (0.39) | MAPK1ALDH1A1 | |
| SCHEMBL21518306 | 0.82 | MAPK1 (0.42) | MAPK1 | |
| SCHEMBL13702970 | 0.81 | LMNA (0.42) | MAPK1ALDH1A1 | |
| SCHEMBL24627914 | 0.81 | LMNA (0.54) | MAPK1 | |
| SCHEMBL21162437 | 0.81 | MAPK1 (0.33) | MAPK1ALDH1A1TDP1 | |
| SCHEMBL18609228 | 0.81 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL13702974 | 0.79 | LMNA (0.40) | MAPK1ALDH1A1 | |
| SCHEMBL24627511 | 0.79 | LMNA (0.40) | MAPK1ALDH1A1 | |
| SCHEMBL13702972 | 0.79 | LMNA (0.40) | MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924548-A | Catalyst component for olefin polymerization, preparation method, catalyst system and olefin polymerization method | 中国石油化工股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023171326-A1 | METHOD FOR PRODUCING ALKENE | 株式会社クレハ | 2023-09-14 | — | — | WO | disclosed |
| WO-2023171325-A1 | METHOD FOR PRODUCING ALKENE | 株式会社クレハ | 2023-09-14 | — | — | WO | disclosed |
| US-11718618-B2 | Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230159528-A1 | VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11186531-B2 | Production method for alkene | KUREHA CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | KUREHA CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005116655-A2 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NOBEX CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050176900-A1 | Spherical catalyst for olefin polymerization | ENGELHARD CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-0646103-B1 | BF3-TERTIARY ETHERATE COMPLEXES FOR ISOBUTYLENE POLYMERIZATION | AMOCO CORP (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0646103-A4 | BF 3?-TERTIARY ETHERATE COMPLEXES FOR ISOBUTYLENE POLYMERIZATION. | AMOCO CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0646103-A1 | BF 3?-TERTIARY ETHERATE COMPLEXES FOR ISOBUTYLENE POLYMERIZATION. | AMOCO CORP (US) | 1995-04-05 | — | — | EP | disclosed |
| WO-1993010063-A1 | BF3-TERTIARY ETHERATE COMPLEXES FOR ISOBUTYLENE POLYMERIZATION | AMOCO CORPORATION (US) | 1993-05-27 | — | — | WO | disclosed |
| US-5068490-A | Alkyl tert-butyl ether boron trifluoride complex as a catalyst | AMOCO CORPORATION (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0004335-A2 | Prostacyclin analogs, process and intermediates for their preparation and their use as medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-03 | — | — | EP | disclosed |
| EP-0001270-A1 | Analogues of prostacycline, methods for their preparation and their use in the treatment of circulatory diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | MAPK1 11/4885ALDH1A1 1973/4885CA12 4870/4885 |
| US-11718618-B2 | Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors | SLC18A2, SLC6A2, SLC18A1 | MAPK1 1519/4885ALDH1A1 255/4885CA12 4875/4885 |
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | ALK, ALKBH3, ALKBH1 | MAPK1 3808/4885ALDH1A1 299/4885CA12 257/4885 |
| US-11186531-B2 | Production method for alkene | ALK, ALKBH3, ALKBH1 | MAPK1 3808/4885ALDH1A1 299/4885CA12 257/4885 |
| US-20230159528-A1 | VMAT2 INHIBITORS AND METHODS OF USE | SLC18A2, SLC6A3, SLC6A2 | MAPK1 3650/4885ALDH1A1 749/4885CA12 4473/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | MAPK1 4217/4885ALDH1A1 1759/4885CA12 4092/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | MAPK1 4217/4885ALDH1A1 1759/4885CA12 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.